What is the most serious side effect of dasatinib?

Dasatinib (Dasatinib) is a targeted drug used to treat certain types of leukemia. Although it is outstanding in controlling cancer, it also comes with a series of potentially serious side effects. Among them, pulmonary arterial hypertension (PAH) is considered to be one of the most serious side effects.

Pulmonary hypertension is a rare but extremely dangerous condition that causes abnormally high blood pressure in a patient's lungs, affecting heart function and overall health. The occurrence of PAH is not uncommon in patients taking dasatinib, especially during the period after taking the drug. According to the FDA announcement, symptoms of pulmonary hypertension include shortness of breath, fatigue, and swelling of body parts such as ankles and legs. These symptoms not only affect quality of life but may also lead to more serious complications.

In clinical studies, dasatinib use has been associated with multiple cases of pulmonary hypertension, particularly after more than one year of treatment. It is important to note that this side effect does not occur in all patients, but when it does, it often requires medical intervention. During treatment, some patients may face further tests, such as cardiac ultrasound and right heart catheterization, to accurately assess the pressure in the pulmonary arteries and its impact on the heart.

In addition, in addition to pulmonary hypertension, dasatinib may cause other serious adverse reactions, including neutropenia and bone marrow suppression. These conditions may cause a patient's immune system to be suppressed, increasing the risk of infection. In some clinical trials, it was observed that approximately 18% of patients developed pleural effusion and required treatment by aspiration or pleurodesis. While not every patient will experience these side effects, the impact on their health is clear.